Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814170 | 0.93 | AAK1 (0.41) | AAK1GAASIRT2SIRT1KDM4C | |
| SCHEMBL21791260 | 0.86 | GAA (0.38) | GAASIRT2SIRT1KMT2AL3MBTL1 | |
| SCHEMBL21178544 | 0.86 | GAA (0.44) | AAK1GAASIRT2SIRT1KMT2A | |
| SCHEMBL21179064 | 0.86 | GAA (0.44) | AAK1GAASIRT2SIRT1KMT2A | |
| SCHEMBL31704461 | 0.86 | GAA (0.44) | AAK1GAASIRT2SIRT1KMT2A | |
| SCHEMBL4146006 | 0.84 | AAK1 (0.41) | AAK1GAASIRT2SIRT1TRPV1 | |
| SCHEMBL29279142 | 0.83 | GAA (0.40) | AAK1GAAALDH1A1SIRT2SIRT1 | |
| SCHEMBL24703836 | 0.81 | PRMT5 (0.42) | AAK1GAASIRT2SIRT1KMT2A | |
| SCHEMBL29977526 | 0.81 | PRMT5 (0.42) | AAK1GAASIRT2SIRT1KMT2A | |
| SCHEMBL23976524 | 0.81 | KDM4C (0.42) | ALDH1A1KMT2AKDM4CMAPK1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | AAK1 2086/4885GAA 1125/4885ALDH1A1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.